The reiteration of a Buy rating and a significant price target of $50 by a reputable analyst firm like HC Wainwright & Co. is likely to instill confidence among investors and could lead to a positive short term impact on Actinium Pharma's stock price. The analyst's bullish stance suggests a strong belief in the company's future performance.